Supernus Pharmaceuticals (NASDAQ:SUPN) Price Target Raised to $38.00 at Piper Sandler
Supernus Pharmaceuticals (NASDAQ:SUPN) Price Target Raised to $38.00 at Piper Sandler
Supernus Pharmaceuticals (NASDAQ:SUPN – Get Rating) had its price objective boosted by Piper Sandler from $33.00 to $38.00 in a research note issued to investors on Wednesday morning, The Fly reports. They currently have an overweight rating on the specialty pharmaceutical company's stock.
据The Fly报道,派珀·桑德勒周三上午向投资者发布的一份研究报告将Supernus PharmPharmticals(纳斯达克:SUPN-GET评级)的目标价从33美元上调至38美元。他们目前对这家专业制药公司的股票给予了增持评级。
Supernus Pharmaceuticals Trading Up 2.2 %
Supernus制药公司股价上涨2.2%
Shares of SUPN opened at $34.23 on Wednesday. The stock's 50 day moving average is $31.35 and its two-hundred day moving average is $30.22. The firm has a market capitalization of $1.83 billion, a PE ratio of 33.89 and a beta of 1.04. Supernus Pharmaceuticals has a twelve month low of $24.95 and a twelve month high of $36.08.
周三,SUPN的股价开盘报34.23美元。该股的50日移动均线切入位为31.35美元,200日移动均线切入位为30.22美元。该公司的市值为18.3亿美元,市盈率为33.89倍,贝塔系数为1.04。Supernus PharmPharmticals的12个月低点为24.95美元,12个月高位为36.08美元。
Supernus Pharmaceuticals (NASDAQ:SUPN – Get Rating) last issued its quarterly earnings results on Thursday, August 4th. The specialty pharmaceutical company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.15). The business had revenue of $170.10 million during the quarter, compared to analyst estimates of $164.23 million. Supernus Pharmaceuticals had a net margin of 9.12% and a return on equity of 6.98%. The company's revenue was up 20.4% on a year-over-year basis. During the same quarter last year, the firm posted $0.43 earnings per share. On average, sell-side analysts predict that Supernus Pharmaceuticals will post 1.51 EPS for the current year.
超威制药(纳斯达克代码:SUPN-GET评级)最近一次发布季度收益报告是在8月4日(星期四)。这家专业制药公司公布本季度每股收益为0.14美元,低于普遍预期的0.29美元(0.15美元)。该业务本季度营收为1.701亿美元,而分析师预期为1.6423亿美元。Supernus制药公司的净利润率为9.12%,股本回报率为6.98%。该公司的收入同比增长了20.4%。去年同一季度,该公司公布的每股收益为0.43美元。卖方分析师平均预测,Supernus PharmPharmticals本年度每股收益将达到1.51股。
Insider Buying and Selling at Supernus Pharmaceuticals
Supernus制药公司的内幕买卖
Hedge Funds Weigh In On Supernus Pharmaceuticals
对冲基金参与Supernus PharmPharmticals
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SUPN. ProShare Advisors LLC boosted its stake in shares of Supernus Pharmaceuticals by 4.4% during the 4th quarter. ProShare Advisors LLC now owns 19,862 shares of the specialty pharmaceutical company's stock valued at $578,000 after buying an additional 843 shares during the period. State Board of Administration of Florida Retirement System raised its holdings in Supernus Pharmaceuticals by 4.3% in the 4th quarter. State Board of Administration of Florida Retirement System now owns 97,789 shares of the specialty pharmaceutical company's stock worth $2,852,000 after acquiring an additional 3,997 shares during the period. Bank of America Corp DE raised its holdings in Supernus Pharmaceuticals by 10.9% in the 4th quarter. Bank of America Corp DE now owns 534,919 shares of the specialty pharmaceutical company's stock worth $15,597,000 after acquiring an additional 52,661 shares during the period. Natixis Advisors L.P. raised its holdings in Supernus Pharmaceuticals by 22.5% in the 4th quarter. Natixis Advisors L.P. now owns 26,997 shares of the specialty pharmaceutical company's stock worth $787,000 after acquiring an additional 4,953 shares during the period. Finally, First Republic Investment Management Inc. grew its position in Supernus Pharmaceuticals by 5.9% in the 4th quarter. First Republic Investment Management Inc. now owns 22,595 shares of the specialty pharmaceutical company's stock worth $659,000 after purchasing an additional 1,262 shares during the last quarter. Institutional investors and hedge funds own 99.81% of the company's stock.
一些对冲基金和其他机构投资者最近增持或减持了SUPN的股份。ProShare Advisors LLC在第四季度将其在Supernus PharmPharmticals的股份增加了4.4%。ProShare Advisors LLC现在拥有这家专业制药公司的19862股,价值578,000美元,在此期间又购买了843股。佛罗里达州行政管理委员会退休系统在第四季度将其在Supernus PharmPharmticals的持股增加了4.3%。佛罗里达州行政管理委员会退休系统现在拥有97,789股这家专业制药公司的股票,价值2,852,000美元,在此期间额外购买了3,997股。美国银行DE在第四季度增持Supernus PharmPharmticals的股份10.9%。美国银行DE现在拥有534,919股这家专业制药公司的股票,价值15,597,000美元,在此期间又购买了52,661股。Natixis Advisors L.P.在第四季度将其在Supernus PharmPharmticals的持股增加了22.5%。Natixis Advisors L.P.在此期间额外收购了4953股,现在拥有26,997股这家专业制药公司的股票,价值78.7万美元。最后,First Republic Investment Management Inc.在第四季度将其在Supernus制药公司的头寸增加了5.9%。First Republic Investment Management Inc.现在持有这家专业制药公司22,595股股票,价值65.9万美元,该公司在上个季度又购买了1,262股股票。机构投资者和对冲基金持有该公司99.81%的股票。
Supernus Pharmaceuticals Company Profile
Supernus制药公司简介
(Get Rating)
(获取评级)
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age.
Supernus制药公司是一家生物制药公司,在美国专注于治疗中枢神经系统(CNS)疾病的产品的开发和商业化。它的商业产品是Trokendi XR,这是一种用于治疗癫痫和预防偏头痛的托吡酯缓释剂;奥克泰拉XR是一种缓释型奥卡西平,用于单一疗法治疗6至17岁的成人和儿童部分发作癫痫。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Supernus Pharmaceuticals (SUPN)
- Can Alibaba And Baidu Finally Rally With Delisting Fears Gone?
- 3 Materials Stocks That May Earn a Place on Your Watchlist
- Is World Wresting Entertainment Getting Ready to Be Sold?
- Crowdstrike Stock Retraces, As Earnings Sober Expectations
- Will The Institutions Buy The Dip In Ambarella Stock?
- 免费获取StockNews.com关于Supernus制药公司的研究报告(SUPN)
- 阿里巴巴-SW和百度集团-SW最终能在退市恐惧中重整旗鼓吗?
- 3种可能在你的观察名单上获得一席之地的材料类股
- 世界摔跤娱乐公司准备被出售了吗?
- CrowdStrike股价回落,盈利超出预期
- 这些机构会在安巴雷拉入股抄底吗?
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
获得Supernus PharmPharmticals Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Supernus制药公司和相关公司的最新新闻和分析师评级的每日摘要。